Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Phase IIb study of mesdopetam for the treatment of dyskinesias in Parkinson’s disease

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses the results from the IRL790C005 study, a randomized, double-blind, placebo-controlled Phase IIb trial evaluating the efficacy of mesdopetam on daily on-time without troublesome dyskinesia in patients with Parkinson’s disease. Mesdopetam, acting as a partial dopamine receptor antagonist, showed promising results in the multicenter study, significantly improving dyskinesias. Although this was a preliminary study, further research is needed to establish the drug’s efficacy in a larger population. Dyskinesias, especially troublesome ones, have been difficult to treat, with limited options such as deep-brain stimulation and infusion therapies. If proven effective in future studies, mesdopan could revolutionize the treatment approach for this challenging aspect of Parkinson’s disease. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.